People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...
A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!
New dyslipidemia guidance from the American Association of Clinical Endocrinology focuses on newer medications and ...
It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback